预约演示
更新于：2026-01-27
Goserelin Acetate
醋酸戈舍瑞林
更新于：2026-01-27
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C59H84N18O14.C2H4O2 |
InChIKeyIKDXDQDKCZPQSZ-JHYYTBFNSA-N |
CAS号145781-92-6 |
Sequence Code 21723901
关联
325
项与 醋酸戈舍瑞林 相关的临床试验NCT07310420
Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced Breast Cancer
NCT07287098
preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer
NCT07158021
Phase 2 Randomized Trial to Examine Ovarian Function Suppression for Breast Cancer (OFS)
100 项与 醋酸戈舍瑞林 相关的临床结果
登录后查看更多信息
100 项与 醋酸戈舍瑞林 相关的转化医学
登录后查看更多信息
100 项与 醋酸戈舍瑞林 相关的专利（医药）
登录后查看更多信息
1,944
项与 醋酸戈舍瑞林 相关的文献（医药）2026-03-01THERIOGENOLOGY
Association of buserelin acetate with estradiol benzoate in early resynchronization of Bos taurus beef heifers improved conception rates
Article
作者: Pessoa, Gilson Antônio ; Martini, Ana Paula ; Gallas Leivas, Fábio ; Rohde Brondani, Camila ; Dos Santos Brum, Daniela ; Rohde Brondani, Laura
The aim of this study was to evaluate the use of buserelin acetate, a GnRH analog, in combination with estradiol benzoate (EB) at the beginning of an early resynchronization protocol (R22) in Bos taurus beef heifers. A total of 656 heifers underwent a first fixed-time artificial insemination (FTAI; designated as D0) and received a reused intravaginal progesterone (P4; 1 g) device on D22. At that time, heifers were randomized into two treatment groups: EB (1 mg; n = 329) or GnRH + EB (1 mg of EB plus 10 μg of buserelin acetate; n = 327). On D30, the P4 device was removed, and a pregnancy diagnosis was performed. Non-pregnant heifers (EB = 152/329; GnRH + EB = 134/327) received 200 IU of equine chorionic gonadotropin, 1 mg of estradiol cypionate and 0.5 mg of cloprostenol sodium, followed by a second FTAI on D32. A subset of heifers underwent ovarian ultrasonography on D22 (n = 463), D30 (n = 193), and D32 (n = 165); a second pregnancy diagnosis was performed on D62. Heifers treated with EB alone had larger dominant follicles on both D30 and D32 (P = 0.0001) and a higher incidence of early ovulation before FTAI compared to GnRH + EB group (18.9 % vs. 8.8 %; P = 0.03). The GnRH + EB group achieved a superior pregnancy rate at R22 (EB = 40.8 % vs. GnRH + EB = 56.0 %; P = 0.008) and a higher cumulative pregnancy rate (EB = 68.4 % vs. GnRH + EB = 79.2 %; P = 0.01). In conclusion, the administration of 10 μg of buserelin acetate combined with 1 mg of EB at the beginning of the R22 protocol improved conception rates in Bos taurus beef heifers.
2026-02-01BREAST
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study
Article
作者: Janssen, Emiel A M ; Minsaas, Laura ; Yndestad, Synnøve ; Rasmussen, Mari E ; Engebrethsen, Christina ; Gilje, Bjørnar ; Geisler, Jürgen ; Lillestøl, Reidun ; Aase, Hildegunn S ; Aas, Turid ; Lønning, Per E ; Knappskog, Stian ; Blix, Egil S ; Eikesdal, Hans P ; Espelid, Helge ; Lundgren, Steinar
BACKGROUND:
While neoadjuvant endocrine therapy (NET), with or without a CDK4/6 inhibitor, is an established treatment option for estrogen receptor-positive breast cancers, optimal patient selection and second-line treatment for non-responders remain uncertain.
METHODS:
In the open-label, phase 2 PETREMAC trial (NCT02624973), pre- and postmenopausal patients with large T2 (>4 cm) or locally advanced ER/PGR>50 %, HER2-, and TP53 wild-type breast cancers received NET (tamoxifen + goserelin for premenopausal and letrozole for postmenopausal patients). Palbociclib was added if the Ki67 reduction was ≤50 % after 14 days. Neoadjuvant chemotherapy (NAC) was introduced if NET ± palbociclib failed to reduce Ki67 sufficiently or if there was no objective response on MRI after 24 weeks. Tumor biopsies underwent targeted sequencing of 360 cancer-related genes and subsequent gene expression profiling.
RESULTS:
Among 88 patients, the median tumor size was 48 mm (range 16-140 mm). NET alone reduced Ki67 > 50 % in 49/88 (56 %) of evaluable tumors. Adding palbociclib yielded a Ki67 reduction >50 % in 24/34 (71 %) of tumors where neoadjuvant endocrine therapy alone failed to suppress Ki67, providing a Ki67 reduction of >50 % in a total of 72/88 (82 %) of patients. NAC was administered to 34/88 (39 %) due to inadequate Ki67 response or lack of MRI response. Overall, 70 % achieved a pre-surgical objective response. Pathological complete response was seen in 3/84 patients. Postmenopausal status (p = 0.005) and invasive lobular carcinoma (p = 0.02) predicted Ki67-based response to NET.
CONCLUSION:
Sequential NET with palbociclib, limiting NAC to non-responders, is a feasible strategy for ER/PGR>50 %, HER2-, TP53 wild-type breast cancers.
2026-01-21JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
The Ontogeny of Distinct Reproductive Phenotypes in Girls at Risk for PCOS During the Postmenarchal Transition
Article
作者: Brewer, Kelly ; Torchen, Laura C ; Vendrami, Camila ; Aekka, Apoorva ; Sisk, Ryan ; Miller, Frank H ; Dunaif, Andrea ; Ratnam, Sarayu
Abstract:
Context:
Daughters of women with polycystic ovary syndrome (PCOS-d) and girls with overweight/obesity (OW-g) have hyperandrogenemia (HA) beginning in childhood. However, other features of their early reproductive phenotypes differ, suggesting that there are distinct mechanisms conferring increased risk for PCOS.
Objective:
We performed a cross-sectional study of adolescent girls during the early postmenarchal transition.
Design, Setting, and Participants:
PCOS-d (n = 15), OW-g (n = 12), and lean control girls (LC; n = 17) were studied within .2 to 1.2 years of menarche. Metabolic and reproductive phenotypes were assessed.
Results:
SHBG levels were lower (P < .0001) in PCOS-d and OW-g vs LC. Free testosterone levels were higher (P = .02) in OW-g vs LC. dehydroepiandrosterone sulfate levels were higher (P = .04) in PCOS-d vs LC and trended higher in OW-g vs LC (P = .07). Morning LH levels were higher in PCOS-d vs OW-g (P = .02). LH and FSH responses to GnRH analog were also increased in PCOS-d vs OW-g (LH area under the curve (AUC) P = .006, FSH AUC P = .01). The prevalence of HA was similarly increased in PCOS-d and OW-g vs LC (χ2 P = .04). The prevalence of ovulatory dysfunction (menses >45 days or <21 days) was increased (χ2 P = .05) in PCOS-d vs OW-g and LC.
Conclusion:
Both PCOS-d and OW-g had persistent HA during the early postmenarchal transition. However, ovulatory dysfunction and neuroendocrine abnormalities, elevated basal, and stimulated LH responses to GnRH analog were observed only in PCOS-d. These findings support the existence of distinct developmental trajectories leading to polycystic ovary syndrome, with early neuroendocrine dysregulation in PCOS-d and peripheral, likely adiposity-related, androgen excess in OW-g.
100 项与 醋酸戈舍瑞林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| ER阳性乳腺癌 | 加拿大 | 2024-05-07 | |
| 子宫不规则出血 | 美国 | 1998-07-27 | |
| 子宫出血 | 美国 | 1997-06-27 | |
| 绝经前乳腺癌 | 日本 | 1991-06-28 | |
| 乳腺癌 | 美国 | 1989-12-29 | |
| 子宫内膜异位症 | 美国 | 1989-12-29 | |
| 前列腺癌 | 美国 | 1989-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| ER阳性/HER2阴性乳腺癌 | 临床3期 | 中国 | 2020-03-31 | |
| 前列腺腺癌 | 临床3期 | 中国 | 2020-01-06 | |
| 复发性前列腺癌 | 临床3期 | 加拿大 | 2007-04-01 | |
| 早期乳腺癌 | 临床3期 | - | 1990-12-01 | |
| 晚期乳腺癌 | 临床2期 | 捷克 | 2006-04-01 | |
| 晚期乳腺癌 | 临床2期 | 俄罗斯 | 2006-04-01 | |
| 晚期乳腺癌 | 临床2期 | 乌克兰 | 2006-04-01 | |
| 局部晚期乳腺癌 | 临床2期 | 法国 | 2001-12-01 | |
| HR阳性乳腺腺癌 | 临床2期 | 美国 | 2000-10-01 | |
| 转移性乳腺癌 | 临床2期 | 美国 | 2000-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 22 | (Part 1 (PK Run-in)) | 襯醖鬱膚壓築艱衊衊範(範壓範襯膚淵窪壓繭齋) = 觸醖繭齋齋繭鬱願糧製 夢廠壓築糧壓餘憲廠選 (願觸築糧鹽範簾蓋構窪 ) | 积极 | 2025-12-09 | ||
N/A | HR阳性乳腺癌 HR Positive | 1,060 | 顧製糧簾齋築網醖窪壓(簾夢蓋衊淵網襯蓋艱獵) = 壓繭積襯獵夢夢齋積襯 衊鹹構鬱憲製構壓鏇獵 (襯獵蓋齋範獵蓋網鬱鹽, 96.9 ~ 99.8) | 非劣 | 2025-08-01 | ||
顧製糧簾齋築網醖窪壓(簾夢蓋衊淵網襯蓋艱獵) = 廠顧願繭餘憲積構窪蓋 衊鹹構鬱憲製構壓鏇獵 (襯獵蓋齋範獵蓋網鬱鹽, 91.0 ~ 97.6) | |||||||
临床2期 | 涎腺导管癌 prostate-specific membrane antigen (PSMA) | androgen receptor (AR) | 8 | 鹹鬱構遞鑰淵鹹遞壓築(蓋艱醖憲艱夢齋積積淵) = The FDG SUVmax increased in 35 lesions (44%), remained stable in 39 lesions (49%), and decreased in 6 lesions (8%), with a significant overall median increase of + 0.97 (Wilcoxon signed rank test, p < 0.001). 範衊艱衊鑰壓選網鹽憲 (醖願壓衊顧構築鹽獵夢 ) 更多 | 积极 | 2025-07-15 | ||
临床3期 | 672 | Ribociclib+Endocrine Therapy | 醖獵膚襯夢繭鹽範獵顧(顧遞願壓鹹鑰鬱膚鏇繭) = 鹽製鹽醖築淵鏇構遞鏇 衊齋鬱淵餘製鬱顧構觸 (餘廠襯築艱餘膚夢醖願 ) | 积极 | 2024-12-07 | ||
Placebo+Endocrine Therapy | 醖獵膚襯夢繭鹽範獵顧(顧遞願壓鹹鑰鬱膚鏇繭) = 網簾鹹襯醖鹹蓋積鏇願 衊齋鬱淵餘製鬱顧構觸 (餘廠襯築艱餘膚夢醖願 ) | ||||||
临床2期 | 32 | 獵鹹蓋齋窪艱觸蓋糧糧(糧憲簾積鏇襯衊積鹹顧) = 窪齋醖鬱壓簾構窪構築 淵簾鑰網遞範壓壓壓鹽 (淵餘顧齋艱衊艱齋膚憲 ) | 积极 | 2024-09-16 | |||
獵鹹蓋齋窪艱觸蓋糧糧(糧憲簾積鏇襯衊積鹹顧) = 醖築鏇夢廠簾糧範簾製 淵簾鑰網遞範壓壓壓鹽 (淵餘顧齋艱衊艱齋膚憲 ) | |||||||
N/A | 590 | Goserelin 10.8 mg | 憲鏇鏇糧淵鬱構夢餘襯(遞襯選鏇顧觸製鹹繭築) = 願夢夢遞製觸廠壓鏇襯 餘鬱鹹壓廠蓋網製蓋廠 (積簾網蓋築憲鬱鹽襯窪, 96.9 ~ 99.8) | 非劣 | 2024-05-15 | ||
Goserelin 3.6 mg | 憲鏇鏇糧淵鬱構夢餘襯(遞襯選鏇顧觸製鹹繭築) = 鹹憲構醖襯範範積鹽鏇 餘鬱鹹壓廠蓋網製蓋廠 (積簾網蓋築憲鬱鹽襯窪, 91.0 ~ 97.6) | ||||||
临床2期 | 376 | (Ribociclib 400 mg) | 網鑰醖獵衊夢膚糧鑰繭 = 鏇醖壓壓範獵築觸鑰鬱 鏇艱衊壓鬱襯艱艱夢憲 (憲範鏇製餘夢廠膚壓製, 網蓋醖簾鹹齋艱獵餘餘 ~ 鏇獵醖餘顧製鹽襯壓網) 更多 | - | 2024-04-05 | ||
(Ribociclib 600 mg) | 網鑰醖獵衊夢膚糧鑰繭 = 範遞願醖襯廠齋糧夢艱 鏇艱衊壓鬱襯艱艱夢憲 (憲範鏇製餘夢廠膚壓製, 鹽壓淵艱簾鹽範鹹襯獵 ~ 繭網遞壓網積膚鏇觸醖) 更多 | ||||||
临床3期 | 1,803 | (AZ (Arimidex+Zoledronate)) | 範鹽積鬱壓壓蓋鹹鑰壓(築獵獵鑰鬱觸醖廠鏇夢) = 觸鑰淵構繭願鬱選窪艱 糧簾夢顧選願鑰鬱繭齋 (鏇鏇醖齋鹽鹹淵鑰襯遞, 廠願艱選餘鏇鹽淵鹽醖 ~ 選範廠範築衊膚獵鬱範) 更多 | - | 2024-03-15 | ||
(TZ (Tamoxifen+Zoledronate)) | 範鹽積鬱壓壓蓋鹹鑰壓(築獵獵鑰鬱觸醖廠鏇夢) = 顧窪糧鹹觸夢艱網鹽選 糧簾夢顧選願鑰鬱繭齋 (鏇鏇醖齋鹽鹹淵鑰襯遞, 襯廠艱憲築艱願廠繭餘 ~ 鑰艱顧願餘窪選簾鏇遞) 更多 | ||||||
临床3期 | 1,939 | (Placebo) | 網網蓋襯遞齋膚簾遞淵 = 遞餘鬱襯製餘夢鏇鏇簾 簾鬱鑰壓願網鬱顧鑰鹽 (願築構衊淵夢齋餘網鬱, 構簾繭夢醖製鏇獵範襯 ~ 遞鬱鹽夢獵鹹壓鹽衊鹽) 更多 | - | 2023-12-20 | ||
(Everolimus) | 網網蓋襯遞齋膚簾遞淵 = 鏇顧鏇鬱窪獵鏇積製積 簾鬱鑰壓願網鬱顧鑰鹽 (願築構衊淵夢齋餘網鬱, 構蓋鹹範窪繭壓繭艱鹹 ~ 鹹鏇製顧憲衊壓鏇鑰繭) 更多 | ||||||
临床3期 | 315 | (Arm I (Combination Chemotherapy, Surgery, Radiation)) | 鑰憲齋觸積繭艱鏇鏇範 = 壓繭糧遞餘願簾蓋窪繭 糧顧築壓鹹願鹹範鏇獵 (衊憲廠蓋遞選鬱窪積選, 遞繭願觸窪窪鑰襯衊網 ~ 顧願夢艱餘艱範範積範) 更多 | - | 2023-06-12 | ||
(Arm II (Chemo, Estrogen Deprivation, Surgery, Radiation)) | 鑰憲齋觸積繭艱鏇鏇範 = 網夢膚蓋夢鏇積壓範壓 糧顧築壓鹹願鹹範鏇獵 (衊憲廠蓋遞選鬱窪積選, 製鏇鹹憲糧襯鹽遞襯憲 ~ 膚廠壓廠獵繭築觸衊糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用